The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Advances in the genetics of nonalcoholic fatty liver disease
Curr Opin Gastroenterol. 2023 May 1;39(3):150-155.doi: 10.1097/MOG.0000000000000927. Epub 2023 Mar 1.
1NAFLD Research Center, Division of Gastroenterology.
2Division of Gastroenterology and Hepatology.
3School of Public Health, University of California at San Diego, La Jolla, California, USA.
Abstract
Purpose of review: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the United States and has a strong heritable component. Advances in understanding the genetic underpinnings of NAFLD have revealed important insights into NAFLD pathogenesis, prognosis, and potential therapeutic targets. The purpose of this review is to summarize data on common and rare variants associated with NAFLD, combining risk variants into polygenic scores to predict NAFLD and cirrhosis as well as emerging evidence on using gene silencing as a novel therapeutic target in NAFLD.
Recent findings: Protective variants in HSD17B13, MARC1 and CIDEB have been identified and a confer 10-50% lower risk of cirrhosis. Together, these as well as other NAFLD risk variants, including those in PNPLA3 and TM6SF2, can be combined to create polygenic risk scores associated with liver fat, cirrhosis, and hepatocellular carcinoma. Genomic analysis of extreme phenotypes including patients with lean NAFLD without visceral adiposity may uncover rare monogenic disorders with pathogenic and therapeutic implications and gene silencing strategies targeting HSD17B13 and PNPLA3 are being evaluated in early phase human studies as treatments for NAFLD.
Summary: Advances in our understanding of the genetics of NAFLD will enable clinical risk stratification and yield potential therapeutic targets.